IQVIA Holdings stock holds its ground as investors await fresh data
Published on 07/22/2026 at 05:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IQVIA Holdings (US46266C1053) stock remains tied to a large recurring revenue base, with the company reporting $15.4 billion in revenue, $1.3 billion in net income, and $4.11 diluted EPS in the latest annual reporting context. Those figures give investors a concrete snapshot of the scale behind IQVIA Holdings, even without a fresh event in the material available for this call.
Revenue base above $15 billion
IQVIA said revenue reached $15.4 billion in the latest annual period, while net income came to $1.3 billion and diluted EPS to $4.11. The company also reported a $24.4 billion backlog, a number that matters because it points to future revenue visibility across clinical, commercial, and analytics work.
The comparison is clear in the reported mix: backlog of $24.4 billion is much larger than annual revenue of $15.4 billion, and that spread helps explain why the market tends to focus on contract flow rather than only quarterly swings. For a research and healthcare data business, that relationship is often more informative than a single day of trading.
Backlog and earnings
IQVIA reported $24.4 billion of backlog in the latest annual context, alongside $1.3 billion of net income. The figures suggest a business model built around a long pipeline of contracted work, not one driven by short cycle product sales.
The company also disclosed $4.11 in diluted EPS for the same reporting period. That level gives a direct earnings reference for valuation work and is more useful than a narrative description alone.
IQVIA earnings and backlog
A deeper look at the latest annual revenue, profit, EPS, and backlog figures helps frame IQVIA's data and clinical research franchise.
Clinical work stays central
The representative business line is IQVIA's clinical research and development work, supported by data and analytics services. That mix is the reason the company's backlog and revenue scale matter together: contract depth helps support future utilization across the platform.
In practical terms, a $24.4 billion backlog against $15.4 billion in annual revenue suggests a substantial amount of work already under contract. That is the most relevant operating lens for the stock in the evidence available here.
No quoted price available
The article uses the latest verified reporting figures because no dated market quote is available in the material used for this call. The key reference points remain $15.4 billion in revenue, $1.3 billion in net income, $4.11 diluted EPS, and $24.4 billion in backlog, all in the latest annual reporting context.
IQVIA Holdings stock therefore reads as a numbers-first story: scale, earnings, and backlog rather than a short-term market headline. That makes the annual report context the most useful anchor for readers today.
IQVIA Holdings stock facts
- Company: IQVIA Holdings Inc.
- ISIN: US46266C1053
- Ticker: NYSE: IQV
- Trading venue: NYSE
- Sector / Industry: Health Care / Life Sciences Tools & Services
- Index membership: Not specified in the available material
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
